Donisi Health

Donisi Health is publicly described as a Tel Aviv-based company that developed the Gili Pro BioSensor, a contact-free physiological monitoring system cleared through the FDA De Novo pathway. Public coverage states that the product combines optical sensing with proprietary AI algorithms to analyze micro-vibrations associated with cardiopulmonary activity and produce near real-time physiological estimates. The core proposition is practical rather than purely academic: reduce friction in measurement workflows by removing electrodes, patches, and frequent manual setup, especially in environments where comfort, compliance, and repeatability are major bottlenecks.

From a deep-tech diligence perspective, the company sits at the convergence of sensing hardware, signal processing, and model-driven interpretation. Remote measurement is not unique by itself, but the claimed robustness across different body shapes and skin tones, and through non-contact operation, is strategically relevant if it holds under broad operating conditions. In resilience terms, non-contact monitoring can matter in scenarios where continuous manual instrumentation is operationally expensive or impractical: home-care continuity, surge-response workflows, and settings where minimizing touchpoints or setup time improves throughput. This is where the technology category extends beyond consumer wellness and into infrastructure-like health operations.

The company identity appears to involve a continuity thread with earlier Israeli activity under the ContinUse Biometrics and CU-BX naming lineage. Public sources indicate historical fundraising and leadership from that lineage in Israel, while current public traces show Donisi Health product references alongside CU-BX organizational references. Because branding and corporate presentation are not perfectly unified across available sources, this profile intentionally avoids over-precise claims about legal-entity transitions and instead anchors only to source-supported facts: Israeli roots, contact-free biosensing focus, prior institutional funding history, and documented regulatory progress for a non-contact monitoring device class.

Market context is credible but execution-heavy. The addressable space spans remote patient monitoring, chronic cardiopulmonary management support, telehealth enablement, occupational/driver monitoring, and potentially selected defense-adjacent human-performance or readiness use cases where unobtrusive sensing is favored. Competitive pressure is substantial from wearables, camera-based vital-sign estimators, and integrated digital-health platforms with stronger distribution. Donisi’s defensibility depends on measurement reliability in noisy environments, straightforward clinical integration, reimbursement and procurement pathways, and long-term trust in model performance rather than demo-level novelty.

Strategically, this is a resilience-and-sensing play rather than a direct weapons or offensive-security company. It has plausible dual-use relevance because the same contact-free physiological analytics stack can support civilian healthcare and safety workflows while also mapping to security and defense-adjacent contexts such as personnel monitoring in constrained environments, driver/operator fatigue awareness, and continuity operations during emergencies. The investment and strategic question is therefore not whether the category is useful, but whether this specific team can sustain differentiated accuracy, regulatory-grade evidence generation, and commercial deployment discipline across sectors that demand reliability over hype.

Key diligence gaps remain material: current commercial scale, updated headcount, canonical web presence, and recent financing disclosures are not fully transparent in open sources. For that reason, this record uses calibrated confidence levels and explicit uncertainty markers in stage and risk fields. Even with those caveats, the company remains a relevant Israeli deep-tech ecosystem entry because it represents a technically meaningful intersection of AI-enabled sensing, health resilience, and safety-adjacent monitoring capability.